Konstantin Tachkov

Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries

Brian Godman, Holly McCabe, Trudy Leong et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2020 · 92 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +17

Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents

Meri Amerikova, Ivanka Pencheva, Vania Maslarska et al. · Biotechnology & Biotechnological Equipment · 2019 · 85 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

Evelien Moorkens, Brian Godman, Isabelle Huys et al. · Frontiers in Pharmacology · 2021 · 68 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacology +17

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries

Konstantin Tachkov, Antal Zemplényi, Maria Kamusheva et al. · Frontiers in Public Health · 2022 · 49 citations · Full text

Public Affairs, Health Informatics, Health Policy +13

Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes

Kamila Urbańczyk, Sonja Guntschnig, Vasilis Antoniadis et al. · Frontiers in Pharmacology · 2023 · 47 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacotherapy +17